This protein is identified to influence healthy immune system

Researchers have found through recombinant dog proteins that protein Myb plays a vital role in maintaining the health of our immune system and preventing the development of immune and inflammatory diseases. Preclinical studies have shown that Myb gives immune cells known as regulatory T (Treg) cells "authority" to control the intensity of immune responses. The study was published on Immunity and was led by Dr. Shelia Dias and Professor Stephen Nutt in collaboration with immunologists and bioinformatics teams at the Walter and Eliza Hall Institutes.

Dr. Dias said it was the first sign that Myb had an impact on the immune system. "For decades, Myb has been associated with the formation of multiple types of cancer," Dr. Dias said. "Our study shows that Myb is also important for the function of Treg cells, and we find that at the site where Myb is absent, the ability of Treg cells controlling immune response is also weak, and the immune system continues to respond to a range of threats from mild infections to life-threatening disease. Researchers around the world are investigating how the immune system coordinates and controls health."

"There are many different cell types in the immune system, each with a specific obligation. And when these cells fail to perform their duties, there is a risk of health," Dr. Dias said.

Professor Nutt said, "Increasing the knowledge of the mechanisms that control the immune response is critical to understand how immunization and inflammatory illness occurs and to ultimately develop more effective treatment. If we can figure out how Myb affects Treg cells in the immune system, we may be able to manipulate this activity."

"In the long run, we would like to extend this study to the clinic in order to understand whether our findings can be applied to human immunology," he said. Flarebio provides you with recombinant proteins of good quality including recombinant TLR2.

Scientists have developed new method of cancer immunotherapy

A new generation of cancer immunotherapy has been successful, and this therapy acts on the adaptive immune system, that is, foreign and diseased cells to accurately attack the specialized cells. The other arm of the immune system, known as innate immunity, is not idle in this battle. More research involving in recombinant dog proteins should be conducted.

In a new study in the journal Nature, scientists at the Dana-Farber Cancer Institute report that compounds that can reverse innate immune system cells - transforming them from tumor promoters into tumor antagonists - cause breast cancer in mice to contract withdrawal transfer. When combined with chemotherapy or another immunotherapy, the new compound significantly prolongs the tumor remission. The authors suggest that these findings suggest a way to make a complete composition of the immune system affecting human cancer.

"Most of the current forms of cancer immunotherapy are "taught" by attacking tumor cells or eliminating the barriers to such attacks, affecting the behavior of T cells - leukocytes are part of the adaptive immune system," Guerriero said. "This strategy has been effective against several types of cancer, but usually only a fraction of patients benefit. We hope to see the use of the immune system to produce better results.

The newly-studied target is innate immune system cells called tumor-associated macrophages (TAM). They are usually deeply embedded in the tumor, but they are part of the immune system - the body against the disease defense system - they often promote tumor growth. In this way, they respond to the clues of the tumor itself.

The role of macrophages - both protective and destructive - depends on signals from their environment. In wound healing, for example, macrophages regulate the components of the immune system, removing damaged tissues and restoring affected areas. Tumor macrophages try to hijack these.

In previous studies, scientists from Dana-Farber and colleagues showed that a compound called TMP195 could transform TAMs from helping tumor growth to attacking them. TMP195 converts macrophage responses by altering the genetic activity within TAMs.

In this study, TMP195 significantly reduced the rate of tumor growth in breast cancer mice. They followed the combination of TMP195 with various chemotherapy regimens and an immunotherapy form called T cell checkpoint blockade. In both cases, the combination produces a longer remission of breast cancer than the TMP195 alone. Flarebio provides you with superior recombinant proteins including recombinant Itgb5.

To prevent and treat liver metabolism in new method

Recently, the Nature - Medicine published the latest research results by Professor Li Hongliang research team at the Wuhan University School of Basic Medical Dean online, revealing through recombinant dog proteins for the first time that the natural immune important molecules CFLAR plays key negative regulatory role in nonalcoholic steatohepatitis (NASH) disease, further clarifying its molecular mechanism and having important clinical significance on NASH prevention and treatment.

This study is another major breakthrough in the field of liver metabolic disease research, and it provides a new insight into the understanding of the pathogenesis of NASH, which lays a theoretical foundation for the development of targeted therapy. Professor Li Hongliang told reporters, "CFLAR is an important molecule of the natural immune regulation network. After eight years of research and based on a variety of genetic engineering animal disease model and molecular biology, the team confirmed the key inhibition role of CFLAR on NASH Inflammation, fibrosis, insulin resistance and liver lipid accumulation.

Further in-depth molecular mechanism studies have shown that CFLAR improves and reverses NASH progression by inhibiting the formation of N-dimerization of ASK1 and blocking ASK1 activation. By the way, Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers good-quality recombinant proteins like recombinant Aoc3 for your research at reasonable prices.

Gene editing technology helps tomatoes flower and mature two weeks in advance

Research team at Cold Spring Harbor Laboratory (CSHL) made use of CRISPR gene editing technology to make tomatoes flowering and maturing two weeks more in advance and to expand the scope of this important crop cultivation. The study was published in the journal Nature Genetics which has also publishes other studies on recombinant dog proteins.

"We show the strong ability of CRISPR to rapidly enhance crop traits," said Zachary Lippman, associate professor of CSHL. The technology is not only suitable for tomatoes, but also can be used for corn, soybeans, wheat and other major crops.

Lippman and his colleagues studied a wild tomato in the Galapagos Islands. The Galapagos Islands are located near the equator, and the day and night time are nearly 12 hours a year.

The wild tomatoes of the Galapagos Islands go to the place with long summer, and it will be very late to flower and bear fruit. Studies have shown that this tomato is extremely sensitive to sunshine length. The longer the daytime, the longer the flowering time; the shorter the daytime, the shorter the flowering time.

Flowering time is regulated by a hormone system, and florigen and anti-florigen SP (SELF PRUNING) to work together. Researchers have found that domesticated tomatoes are not as sensitive as wild tomatoes to day length because of the SP5G mutations that have been acclimated to tomatoes. When wild tomatoes on the Galapagos Islands grow in New York, the SP5G gene-coded anti-florigen show rapid increase in the level of expression and activity, resulted in the flowering of the plants for a long time. In contrast, this increase in anti-florigen in domesticated tomatoes is much weaker.

Researchers use gene editing tool CRISPR to induce SP5G gene mutations that do not produce any anti-chaperonin proteins. Studies have shown that such editors make the common tomato varieties earlier. In addition, manipulating another chlamydia gene will make the tomato grow as dense as the shrubs and show precocity fruiting. By the way, Flarebio offers recombinant proteins of good quality like recombinant Itgb5 at competitive prices.

Diabetics with early kidney disease lack protective "anti-aging" hormones Klotho

A new study by King's College London showed that diabetics with early kidney disease lack protective "anti-aging" hormones Klotho. Klotho protein is a new type of anti-aging-related proteins that play an important role in resisting body aging. Klotho is secreted by the kidneys. Studies using recombinant dog proteins have shown that secreted Klotho protein can inhibit the aging of the body, play the role of anti-oxidation, anti-apoptotic and protect the cardiovascular, kidney and other systems so as to regulate a variety of aging-related diseases.

A study published on Feb. 13 in the European Diabetes Research Association journal Diabetologia shows that Klotho may play an important role in the development of common kidney disease in diabetic patients. This means that Klotho's expression level may serve as a potential marker for predicting the risk of kidney disease, as well as developing new targets for the treatment and prevention of kidney disease in patients with type 1 diabetes. The preliminary work of the research team also shows that Klotho protects the vascular system from changes associated with abnormal aging, such as arterial wall thickening (atherosclerosis), which characterizes age-related diseases such as diabetes, heart disease and hypertension.

In this study, scientists studied blood and urine samples from 78 patients with type 1 diabetes, 33 of which showed signs of early stage of diabetic nephropathy (known as microalbuminuria). The researchers found that Klotho levels in the blood of patients with microalbuminuria were lower in patients with microalbuminuria than those without microalbuminuria. Klotho levels in patients without microalbuminuria were the same as those for healthy adults.

"This is the first time that Klotho has been associated with type 1 diabetic nephropathy," said Dr. Giuseppe Maltese of the first author of the study at the King's College London. "This finding means that new disease markers and potential treatments can be developed."

"With further research, through the larger type 1 and type 2 diabetes patients, we hope to expand the scope of this study in order to identify early high-risk patients in the progress of kidney disease and cardiovascular disease," said Dr. Janaka Karalliedde, senior author.

Researchers say the study will help scientists better understand how this hormone contributes to healthy aging and how Klotho's flaws lead to age-related illnesses. As part of the ARK (King Academy Aging Research) research program, they are further researching Klotho's role in aging and longevity.

The limitations of this study include its relatively small sample size and selectivity, making it impossible for researchers to determine the causal relationship between Klotho and kidney disease progression. By the way, Flarebio provides you with recombinant proteins of good quality such as recombinant Ptpra.

New drugs for the treatment of multiple myeloma patients

Multiple myeloma is a cancer of bone marrow plasma cells. Plasma cells produce certain proteins that establish the immune system. According to research using recombinant dog proteins, when the number shows abnormalities, these proteins damage the body and the immune system.

"We are now able to diagnose and treat myeloma earlier before it begins to damage the body, thus effectively controlling myeloma, and any irreversible damage to the body may be significantly delayed," said Dr. Sikander Ailawadhi, haematologist and oncologist from Jacksonville Mayo Clinic Cancer Center.

In 2015, the US Food and Drug Administration approved three new drugs for the treatment of multiple myeloma in two weeks. "The approval of these drugs for the treatment of diseases that are considered to be incurable in such a short period of time is unprecedented," Ailawadhi said. "Most patients showed symptom relief, and their survival rate has been improved."

"We can almost guarantee that every patient who has been diagnosed with newly diagnosed myeloma has a certain degree of reaction," he added.

"Some of the most exciting things are the development of new drugs," Ailawadhi explained. "Specifically, we can use the currently available drugs to observe what resistance to drive myeloma cells and to isolate those pathways and then to develop new drugs that specifically target those resistance mechanisms."

Ailawadhi says that more drugs are coming soon. At present, the Mayo Clinic has more than 50 active clinical trials. Flarebio offers recombinant proteins of good quality such as recombinant ECEL1.

To study protein dynamics in a new way

Researchers have developed the first computational method based on evolutionary principles to predict protein dynamics. These researchers are from the Structural Biology Computational Group of the Spanish National Cancer Research Centre (CNIO), led by Alfonso Valencia, together with a group led by Francesco Gervasio at the University College London (UK). Protein dynamics can explain the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions. This study push the development of the computational study of protein dynamics, and it is helpful for the design of drugs and for the research about genetic disease. It is published in the journal Proceedings of the National Academy of Sciences (PNAS), which also publishes other studies on recombinant dog proteins.

As we know, proteins are crucial to the thousands of cellular functions which work in a living organism. It is chains of smaller molecules which are called amino acids that form the protein - a three-dimensional structure. By studying the co-evolution of amino acids, we can reconstruct the form or structure of these biological compounds in their natural surroundings. We can also predict physical contacts between amino acids with higher accuracy and in sufficient number by analyzing the sequences of a given family of proteins, to reconstruct the folding and structure of a protein accurately.

Nevertheless, the structure won't remain changeless. It interacts with other biological compounds or with drugs, which is called protein dynamics. The study about it turns out to be extremely difficult no matter through experimental observations or computational tools.

"We developed a model in which the amino acids that have a strong co-evolutionary relationship attracted each other, without further additional data," says Simone Marsili, researcher who has also participated in the project. "First, we simulate the folding process and then we can see how the simulations were able to predict the changes in shape of the proteins at different levels of complexity, including those required for kinases to function." Flarebio offers superior recombinant proteins like recombinant TLR2 at competitive prices.

The gene Gpr182 has been caught to treat gastrointestinal cancer

Recently, an article published in the journal Clinical Medicine states that scientists have finally seized the Gpr182. Over the years, Gpr182 is like a fugitive criminal, so scientists are helpless. Studies using recombinant dog proteins have shown that Gpr182 can open the door for the treatment of gastrointestinal cancers if a solution can be found.

"The good news is that this is a completely new field. It's especially tempting from a medical point of view, because they shed light on the new g-protein-coupled receptor, a class of cell membrane proteins that are well suited to drugs," the researchers say. 40% of the approved drug target at g protein-coupled receptor. Therefore, the discovery of this new receptor plays a huge role for the understanding of gastrointestinal biology and improves the treatment of colon cancer and other diseases. At present, gastrointestinal cancer is the second leading killer cancer in the United States.

After a series of trials, the researchers found that colorectal cancer patients with colorectal cancer had significantly lower Gpr182 expression compared with healthy colon tissue. Further analysis also suggested that Gpr182 expression reduced in breast cancer, lung cancer and other types of cancer.

At the same time, the results suggest that manipulation of Gpr182 expression or activation may provide a new approach for the treatment of cancer, particularly for the treatment of gastrointestinal cancers. Omera Pharmaceuticals claims to have developed a small molecule that intersects Gpr182 and can help speed drug development. Flarebio offers high-quality recombinant proteins like recombinant ITGB5 at competitive prices.

New therapy of multiple myeloma: to inhibit EZH2

In a study using recombinant dog proteins which is published in the scientific journal Oncotarget, researchers from Uppsala University showed how protein EZH2 affects the development of multiple myeloma and that EZH2 can be used as a novel strategy for treating the disease. Multiple myeloma in the form of tumors is still incurable today, and it is a challenge to improve treatment.

Researchers at Uppsala University have previously shown that abnormal chemical modification of DNA-associated proteins (histones) that regulate gene expression patterns can be a potential underlying mechanism for the development of multiple myeloma. The researchers studied the protein EZH2, which involves chemical histone modifications and reduces the survival of tumor cells by treating tumor cells with a substance that specifically inhibits EZH2.

In a recent study, Professor Helena Jernberg discovered a new mechanism at the Department of Genetics and Pathology Immunology that could explain the tumor-promoting effects of EZH2 in multiple myeloma. The researchers analyzed the activity of a large number of genes in tumor cells that had been treated with EZH2 inhibitors, and they found four important oncogenes with lower activity.

"The role of oncogenes in cancer development is to enhance the survival of cancer cells, but not death. In the case when cells can't work, they continue to divide and proliferate. In our study, we have identified four oncogenes. Compared with the control cells, cells treated with the EZH2 inhibitor showed lower activity. And the four genes have previously been shown to be associated with the development of multiple myeloma, confirming our previous finding that EZH2 inhibitors can be used as the treatment of multiple myeloma," Helena Jernberg Wiklund said.

But the researchers were perplexed by the fact that inhibition of EZH2 could reduce the activity of oncogenes. Chemical histone modifications carried out by EZH2 result in lower activity of the affected genes. Thus, inhibition of EZH2 should result in a decrease in the level of chemical modification, which in turn should lead to increased gene activity.

"The answer is that genetic factors called microRNAs have increased activity in the two microRNAs in cells treated with EZH2 inhibitors, and we believe that oncogenes are regulated by these microRNAs. And then when EZH2 is inhibited, histone modifications at the microRNA gene decreases, which leads to increased synthesis of microRNAs and in turn reduces the activity of oncogenes. It is a completely new mechanism for the effect of EZH2," Helena Jernberg Wiklund said. Flarebio provides you with recombinant proteins of good quality such as recombinant ITGB5 at good prices.

To revolutionize the treatment of metastatic uveal melanoma

New research at the University of Liverpool has identified the role of specific proteins in the human body and found that they can help to prevent eye cancer by initiating cancer "cell suicide". The new findings obtained through recombinant dog proteins may help to revolutionize the treatment of metastatic uveal melanoma (UM) - a disease caused by pigment cells (melanocytes) in eyes - and there is currently no effective treatment.

Metastasis is that cancer or other diseases spread from one part of an organ or the body to another, rather than the part directly connected to it. This is the case in about half of all UM patients. Although rare, UM is the most common primary eye cancer in adults. Although primary tumors can usually be treated very effectively, as many as 50% of patients have metastases in the liver, and there is no effective treatment for such metastases.

Dr. Luminita Paraoan from the Department of Ophthalmology and Visual Science at the Institute of Gerontology and Chronic Disease, University of New York, published a new study in the British Journal of Cancer that identified the role of a protein called p63 in UM. Chromosome 3 is one of 23 human chromosomes. People usually have a pair of chromosomes. A portion of chromosome 3 contains the gene of protein p63. Unfortunately, people with aggressive (anti-apoptotic) cells do not have this part, so there is no p63 protein.

Dr. Paraoan found that if the p63 gene is used in combination with another gene called p53, it can effectively target UM and induce cancer cells to undergo apoptosis. The p53 gene is a class of genes from a so-called tumor suppressor gene that is mutated in cancer cases. Tumor suppressor genes are protective genes. Typically, they limit cell growth by monitoring cell division into new cells, repairing damaged DNA and controlling the rate of cell death.

When a tumor suppressor gene is mutated, for example in a cancer case, the cell grows uncontrollably and may eventually form a mass called a tumor. Thus, p53 itself is ineffective in activating apoptosis in UM. "This study highlights for the first time the condition that p63 triggers apoptosis in UM," said Dr. Luminita. "Our results have broad implications for other escape cell-mediated conditions or cancer, and we hope to demonstrate a benefit to the treatment of cancers which have resistance to current chemotherapy and radiotherapy." Flarebio offers recombinant proteins of good quality like recombinant TLR2 at great prices.

New way of identifying subtypes of Alzheimer's disease

Recently, scientists have published an article on early identification of the onset of progressive Alzheimer's disease in the journal Nature which also publishes some other studies on recombinant dog proteins, providing some basis for individual and precise treatment of Alzheimer's disease.

Researchers at the National Institutes of Health and the College of Neurology of the London College of Medicine have found that the type of fibrogenesis is associated with subtypes of Alzheimer's disease. A study published by them on nature described: the formation of brain tissue deposition of amyloid fibrils can reflect the physiological characteristics of Alzheimer's disease. The study found that the type of fiber with the degree of disease and pathological subtypes would show different morphological or size differences. According to this, we can classify the types of early Alzheimer's disease. This is a time-consuming and labor-intensive experimental project, so the relevant research is rare. To investigate the problem, the authors collected 37 tissue samples from the brain tissue of 18 dementia sufferers of the late Alzheimer's disease. They used magnetic resonance techniques to detect the deposition of these brain β-amyloid forms, while the clinical classification of these patients was compared. (Some patients were diagnosed with rapid progression; some patients were diagnosed as classic; and some patients had posterior cortical atrophy). The researchers found that classic patients with cerebral cortical atrophy have the same pattern with patients with cerebral β-amyloid deposition. However, the pattern of amyloid deposition in patients with rapid progression is often different from that of other types of patients.

The researchers believe that the rapid progress of Alzheimer's disease has a special β-like protein deposition pattern, resulting in the condition that the type of brain tissue in patients with fibrous lesions of the size and morphology are different from other types. This helps early identification of rapidly progressing Alzheimer's disease patients and gives them timely treatment. Researchers have also admitted that because the number of specimens is too small, the mechanism is not clear. Further studies remain to be carried out, and greater progress will be made. Flarebio provides you with superior recombinant proteins like recombinant ECEL1 at good prices.

New method of improving obesity is coming!

Recently, the international academic journal Diabetes published a study titled "Deletion of ATF4 in AgRP neurons promotes fat loss mainly via increasing energy expenditure" online by Guo Feifan research group from Institute of Nutrition, Shanghai Institute of Life Sciences, Chinese Academy of Sciences. This study found through research using recombinant dog proteins that activation of transcription factor 4 (ATF4) regulates energy balance and lipid metabolism in hypothalamic-specific neurons of AgRP neurons, providing a potential drug target for the treatment of obesity and related metabolic diseases.

In recent years, both in developing and developed countries or in adults and children, obesity are widely prevalent, and it is closely related to a series of metabolic syndrome such as diabetes, fatty liver, dyslipidemia and cardiovascular diseases, becoming a great threat to human health. Therefore, the study of obesity development mechanism is particularly important. Changes in body weight are caused by imbalances in energy intake and energy expenditure and the central nervous system, especially the hypothalamus, play a key role in regulating energy balance.

Our brain contains a variety of specific types of neurons which have different functions, regulating the body's behavior and metabolic balance. The arcuate nucleus (ARC) of the hypothalamus contains two types of neurons that regulate metabolism: one is appetite-suppressing neurons, such as pro-opioid (POMC) neurons; the other is appetite-promoting neurons, including Neuropeptide Y (NPY) and gerbil peptide gene-related protein (AgRP) neurons. AgRP neurons can release the AgRP protein and inhibit the activity of POMC neurons, thus promoting increased food intake; it also affects energy consumption by adjusting the sympathetic nervous system or leptin sensitivity. The study of how specific neurons such as AgRP regulate energy metabolism will provide an important theoretical basis for the discovery of the etiology and treatment of obesity.

Postdoc DENG Jia-li and Ph.D. student FEI Fei used inducible gene knockout techniques to specifically knock out ATF4 in AgRP neurons of adult mice under the guidance of Guo, finding that these mice were thinner with insulin sensibility and leptin sensibility improved. At the same time, the experimental mice reduced food intake and increased energy consumption, improving the body heat. After high-fat diet, ATF4 mice with AgRP-specific knockout were resistant to high-fat-induced obesity, insulin resistance and fatty liver. Further study of its mechanism of action found that ATF4 can be combined with the promoter of FOXO1 to directly regulate its expression. After injection of FOXO1 adenovirus in the arcuate nucleus of the hypothalamus of the knockout mice, the fat content of mice significantly increased.

In summary, the study found the important function of ATF4 in the hypothalamic AgRP neurons to regulate energy balance and lipid metabolism, suggesting that the treatment of obesity and metabolic diseases, ATF4 may become a new drug target. Flarebio provides you with high-quality recombinant proteins like recombinant PIGR at competitive prices.

Melanoma can be treated by interleukin-9 protein

US researchers found through research involving recombinant dog proteins that a protein has the efficacy of treating the skin cancer melanoma. This protein can be synthesized by the human body, so it is expected to develop new treatment to promote the body to fight against melanoma on this basis.

Melanoma is a malignant skin cancer, and the mortality rate is high. The researchers from Harvard University School of Medicine and other institutions conducted research on some melanoma patients with tissue samples and found that compared with normal levels, the patient code number for the interleukin-9 protein content is much lower or even missing.

The researchers also explored the effect of this protein on melanoma through animal experiments, and the results showed that if the mice injected with the inhibitory effect of interleukin-9 substances, the melanoma they suffer will grow rapidly, which is similar to human patients who have this protein in vivo.

However, if mice were injected with substances that promote an increase in their interleukin-9 levels, the rate at which they develop melanoma will decrease. This suggests that interleukin-9 is a protein that inhibits melanoma.

Interleukin-9 can achieve self-synthesis in the human and experimental mice, and we knew that it is a signal molecule which can mobilize the immune system in the past. The researchers suggested that in the future treatment of melanoma patients, it is suggested to promote the synthesis of more human interleukin-9 to mobilize the power of the immune system itself to inhibit tumor growth. Cusabio provides you with high-quality recombinant proteins such as recombinant Nrg2 at good prices.

To develop novel CRF1 receptor inhibitors is important to treat neuropsychiatric disorders

According to research using recombinant dog proteins, CRF mRNA and CRF are widely distributed in the central nervous system (CNS) and abundant in the hypothalamic paraventricular nucleus (PVN), brainstem, amygdala, hippocampus and neocortex. CRF is a neuropeptide containing 41 amino acids. It is a kind of hormone that regulates the hypothalamic-pituitary-adrenal (HPA) axis of the hypothalamus. It is also the key hormone of neuroendocrine regulation in stress response.

CRF receptors are mainly two seven transmembrane G protein receptors (CRF1, CRF2). CFR and CFR1 have high affinity, but the affinity for CFR2 is weak. In the human body, CFR1 includes five subtypes of α, b, c-h, i, mainly distributed in the anterior pituitary, hippocampus, cerebral cortex and amygdala. Distribution of CFR1 in the anterior pituitary promotes the release of adrenocorticotropic hormone (ACTH) in the hypothalamus, which in turn promotes the release of cortisol from the adrenal cortex; which in turn regulates glucocorticoid receptors (GRs) and mineralocorticoid receptor (MRs) and the signal cascade mediates intracellular responses to stress.

Compared to CRF1, CRF2 is confined to discrete brain regions, such as the dorsal raphe nucleus (DRN), lateral septa (LS), and periaqueductal gray (PAG). CRF2 only has three subtypes: a, b, c. Although the role of CRF2 is less than CRF1, it can antagonize the CRF1-induced stress response. The different roles of CRF1 and CRF2 are also reflected in the distribution of DRN nerve cells. CRF1 is mainly in the cell membrane, while CRF2 is mainly distributed in the cytoplasm. Tension stimulation reverses this distribution, causing CRF to stimulate DRN cells rather than inhibition.

CRF1 and CRF2 have a variety of signaling pathways, the main pathway is CRF1 and CRF2 triggering downstream cascade signals leading to G protein activation, Gαs trigger second messenger cAMP (cyclization of monophosphate), cAMP activation of cAMP protein kinase A (protein kinase A, PKA). They also activate Gαq, activating the cascade of protein kinase C (PKC) and extracellular signal-regulated kinase (ERK) - mitogen-activated protein kinase (MAPK). They can also activate the apoptotic pathway through Akt / protein kinase B, NOS-guanylate cyclase and caspase. Because of this complexity, CRF1 may exchange signals through different channels of the signal.

With the further development of psychopathology, the role of CRF gets more and more attention. Numerous studies have shown that CRF levels are high in patients with neuropsychiatric disorders (including depression, addiction disorder, post-traumatic stress disorder, irritable bowel syndrome, generalized anxiety disorder, etc.) and they also found CRF mRNA increase in the tissues in patients. Subsequent studies have shown that patients are over-expressed in CRF mRNA, resulting in excessive production of CRF. Other studies have demonstrated that increased activity of the CRF1 receptor leads to the development of certain neuropsychiatric disorders. At the same time, it was also demonstrated that specific SNPs are also associated with depression. Therefore, to develop novel CRF1 receptor inhibitors is important for the treatment of neuropsychiatric disorders. Flarebio provides you with good-quality recombinant proteins including recombinant ECE1.

Researchers discover new method of hijacking cells for viruses

DNA contains instructions on how cells make the desired substance. According to research using recombinant dog proteins, when cells need proteins, the relevant parts of the DNA will be transcribed, and transcripts called messenger RNA will leave the nucleus and enter the manufacturing machinery as templates to produce new proteins.

In this process, RNA can be edited in a variety of ways. It may be added to the additional instructions and may also be enemy control. Viruses can edit RNA information to create the version of the protein it needs to produce thousands of copies of the virus. Over the past few decades, biologists have a clearer understanding of how viruses hijack host cells.

Many viruses control the day-to-day running of cells by sending out messages that interfere with the ability to turn off unwanted cellular functions and enhance the functionality they require. But biologists at the University of California, San Diego, have recently discovered that there are some more hijacking mechanisms for viruses that are more subtle and more complex. They don't block cell information but change the content of the information.

The study is published in Nature Structural and Molecular Biology. By the way, Flarebio is a National High-Tech Enterprise with research, production and sales as one. Flarebio provides you with good-quality recombinant proteins like recombinant CDH15 for your research.

New potential treatment of tumor cachexia is coming

Recently, the international academic journal Molecular Therapy published the latest study results of Ding Qiurong Research Group from Chinese Academy of Sciences, Shanghai Institute of Life Sciences Institute of Nutrition Science, and the paper is titled "Prevention of Muscle Wasting by CRISPR / Cas9- mediated Disruption of Myostatin In Vivo". The aim of this study through recombinant dog proteins is to treat myosinophilia by CRISPR in muscle-specific target-knockout myostatin in response to severe muscular dystrophy in cancer patients.

Cachexia can be found in a variety of diseases, of which the cachexia associated with the tumor is most common. Tumor cachexia is a consumptive syndrome shown in many cancer patients, especially in late stages of disease. Although there are sufficient nutrient intake, the substantial loss of skeletal muscle also exist (with or without adiposity), leading to a serious decline in quality of life and survival.

In this study, under the guidance of researcher Ding Qiurong, Wei Yuda, a graduate student achieved used SaCRISPR / Cas9 to target the myostatin signaling pathways that are activated the effect of partly alleviating the cachexia in cachexia through the myostatin in body-targeted knockout muscles aiming at inducing myostatin signaling pathway. The main reasons for choosing myostatin as the target are: 1) myostatin signal pathway is the negative regulator of muscle growth and development. In addition to the muscular system, no serious adverse effects have been found in the natural individuals with myostatin function deletion mutations, and the safety of targeting has been guaranteed. 2) Early serial mice and clinical trials have demonstrated that the myostatin signaling pathway in cachexia (3) myostatin is mainly secreted by the muscle cells. The main mode of action is autocrine / paracrine mode, so the reduction in myostatin concentration in the muscle microenvironment can preserve some of the muscle function in the presence of cachexia.

Based on this, Wei et al. made use of muscle-specific promoter to start the expression of SaCas9 (staphylococcus aureus cas9) and then injected into the glandular-associated virus vector (AAV). After packed in mouse myostatin protein, significant recovery of skeletal muscle function was observed in the tumor-induced cachexia mice model (9% increase in mean skeletal muscle weight, 25% increase in average grip strength, and a slice at the injection site, compared to non-targeted mice staining found muscle fiber atrophy was significantly alleviated). This study as a confirmatory experiment suggests that the use of gene editing specific target knockout myostatin in muscle tissue can be used as a potential gene therapy for cachexia control and can further improve the in-vivo targeting efficiency, and a comprehensive assessment of targeted safety will contribute to its true clinical transformation. Flarebio offers recombinant proteins of great quality including recombinant CDH2 at good prices.

BAG5 protein can save the function of anti-oncoprotein p53

According to research using recombinant dog proteins, among the anti-oncoproteins found so far, p53 is undoubtedly one of the most well-known. It can achieve the curative effect of cancer by affecting cell division, apoptosis, metabolism and other important processes. In nearly half of the tumors, the gene TP53 which expresses this transcription factor show mutations, making p53 lose anti-cancer function. And some functional (GOF) mutations may even make p53 directly "renegade" and promote canceration and tumor resistance.

Mutant p53 is characterized by a greater stability, reflected by being more difficult to be mediated and degradated by ubiquitin ligase MDM2 and CHIP. Interestingly, this stability is limited to cancer cells but not in the normal cells. This allows the mutant p53 to accumulate in the tumor to a high level so as to play its role in promoting cancer. Then, what kind of difference do cancer cells have to make mutant p53 to accumulate at a high level?

Recently, the research team of Prof. Wenwei Hu and Prof. Zhaohui Feng of Rutgers, The State University of New Jersey found that BAG-2-related anti-apoptotic gene (BAG) family proteins BAG5 and BAG2 can prevent pan- Ligase and mutant p53 binding, thereby giving the latter cell-specific stability in the cancer. The results are published in the recent Nature Publishing Group publication Cell Discovery.

In a variety of human breast cancer and lung cancer cell lines and other systems, BAG5 of the five BAG domain can be R175H, R248W or R273H mutant p53 DNA binding domain (DBD) interaction, and BAG5 and wild type P53 between no affinity. At the same time, BAG2, another member of the BAG family, was found to have synergistic effects with BAG5 in enhancing mutant p53 stability. Concomitantly, when BAG5 was overexpressed, the level of mutant p53 was increased in cancer cells, and it decreased when BAG5 was knocked down.

By this interaction, BAG5 prevents MDM2 and CHIP from modifying ubiquitination of mutant p53, thereby ultimately inhibiting degradation of the p53 by the proteasome. Further experiments have shown that BAG5 is essential for the development of functional R248W mutations to play a role in carcinogenesis, including the ability to promote proliferation, proliferation, and drug resistance in cancer cells. It is worth noting that BAG5 is overexpressed in a variety of tumors including breast cancer, skin cancer, colorectal cancer, lung cancer and so on. And the higher the expression level, the worse the prognosis of patients.

BAG family proteins play an important regulatory role in cell division, differentiation and apoptosis, and their common BAG domains have molecular chaperone activity. In this study, BAG5 was found to have proto-oncogenic properties that enhance the ability of cancer cells to proliferate, diffuse and resist drug resistance by increasing the level of functional mutant p53 protein. Therefore, BAG5 has a potential as a therapeutic target for tumors expressing the aforementioned p53 protein. Flarebio provides good-quality recombinant proteins such as recombinant CDH2.

Scientists uncover how plants respond to drought at the molecular level

The sagging and drying of plant leaves suggests that we should water them, but how do plants respond to drought at the molecular level? Scientists at the Salk Institute have recently made a major breakthrough on this issue. This finding might help agricultural production adapt to adverse climates such as drought. The study was published in the Nov. 4 issue of Science. Studies have shown that in the face of unfavorable natural conditions, a small part of the plant proteins would act as a "command" to regulate the complex stress response. These experimental results were conducted using recombinant dog proteins and are expected to contribute to the development of new technologies for improving the use efficiency of plant water.

"At the molecular level, the response of plant to stress is a complex process involving hundreds of genes," said Joseph Ecker, author of the paper. "We have discovered a class of regulatory proteins that play a key role in plant responses to stresses such as drought. And if we can control a regulator protein, it's the equivalent of controlling all the genes it regulates."

Plant roots and leaves would secrete abscisic acid when water is scarce or salinity is high. "Only twenty or several regulatory proteins control the expression of hundreds or even thousands of genes," said Liang Song, the first author of the paper. "By identifying key regulatory proteins and studying their mechanisms of action, we can gain a deeper understanding and even regulate plant responses to stress."

In the experiments, the team at the Salk Institute tracked real-time changes in gene expression during plant secretion of abscisic acid and identified key regulatory proteins. These proteins control plant response to drought stress conditions such as stress response. By locating the binding sites of these regulatory proteins to DNA, they identified key proteins that can regulate gene expression networks, which can efficiently elicit a stressful response to environmental changes. This group focused on studying some of the known regulatory proteins that respond to abscisic acid.

During the experiment, they obtained 122 data sets containing 33,602 genes, of which 3061 genes had at least one time point of change in the expression intensity. Data analysis revealed a multi-level regulatory mechanism, in which regulatory proteins play a key role in gene expression regulation. Interestingly, the binding pattern of a protein at a particular time in DNA can explain much of the expression of a gene over a longer period of time. These kinetic properties together reveal that plant responses to environmental stimuli are a genome-wide synergistic response.

"Based on the understanding of the network structure, we found that a single key regulatory protein can control multiple components, which means that gene regulation is an accurate and interrelated process." Song said. "This is important for agriculture because it suggests that the control of one gene can activate or inhibit another set of genes, making it possible to design a human intervention program as a whole." This study suggests that this multi-level synergistic gene activity may be widespread in flower plants. Flarebio offers good-quality recombinant proteins such as recombinant CDH15 at good prices.

Scientists find the link between DNA and chronic joint pain

Scientists at King's College London have discovered a link between DNA modification and chronic generalized joint pain, one of the main symptoms of fibromyalgia, and the study is funded by the Arthritis Research Foundation. Fibromyalgia is a common chronic condition that causes muscle and bone fatigue and widespread pain. Although fibromyalgia is very popular, the etiology is little understood, and the treatments are limited. What's worse, fibromyalgia can't be detected using routine tests such as scanning or X-ray detection. The disease affects 4% of the world. The study, published in the journal PLOS ONE which also has other studies on recombinant dog proteins, will help scientists develop a diagnosis of fibromyalgia through blood tests.

"Fibromyalgia is affected by genetic factors, but there are a number of complex intermediate processes between genes and diseases," said Frances Williams, Ph.D., one of the authors of the article from the Department of Twin and Genetic Epidemiology. "Identifying measurable epigenetic associations is an important step. What's more, these results will provide information on future studies of fibromyalgia and other chronic pain syndromes, such as irritable bowel syndrome."

Stephen Simpson, director of the British Arthritis Institute, commented on the study, "Millions of people in the UK suffer from fibromyalgia, and this exciting study has helped us understand how individuals' epigenetic differences affect fiber Myalgia and chronic extensive musculoskeletal pain. For people with long-standing fibromyalgia, they have been struggling to diagnose their pain symptoms. This study will help to better understand, manage and treatment joint pain."

The researchers used twins to study whether DNA methylation affects the way genes start up when they produce a particular protein and to observe whether there are differences between musculoskeletal pain patients and non-patients. Scientists have determined that patients with chronic extensive pain and non-patients have different levels of DNA methylation in the three genes. Preliminary indications suggest that people may have different methylation patterns in their DNA and that this may affect the initiation of some genes and may lead to a variety of conditions. Flarebio offers superior recombinant proteins including recombinant Ptpra at good prices.

Scientists discover an antimicrobial peptide to destroy drug-resistant bacteria

In order to deal with the arsenal of bacteria, scientists have taken various different approaches. They no longer develop and improve traditional antibiotics but look to some of the natural antimicrobial substances through recombinant dog proteins. Some of them are fragments of proteins, known as peptide. Recently, researchers from the Massachusetts Institute of Technology, University of Brasilia and the University of British Columbia in Canada designed an antimicrobial peptide that can eliminate many bacteria, including drug-resistant bacteria. This result was published in the Nature Publishing Group Scientific Reports.

Many organisms naturally produce antimicrobial peptides, which are part of the body's own immune system, not only to destroy invading bacteria, but also kill other microorganisms, including fungi and viruses. They have the advantage of acting on bacteria through a number of different mechanisms. First, they can drill holes in the cell membrane that invades the bacteria and can destroy multiple targets, including DNA, RNA, and proteins when inside the bacteria. Second, they can activate the body's own immune system and call the white blood cells to completely eradicate the invasion of microorganisms. This is also the biggest difference between these peptides and traditional antibiotics. In addition, they can also inhibit the immune system due to excessive systemic sepsis.

Naturally-produced antimicrobial peptides are usually composed of 20 amino acids, which include a positively-charged region to help punch in the cell membrane and a hydrophobic region so that it can smoothly go through the cell membrane into the bacteria inside. With the development of modern computing technology, scientists can replace or add new amino acids to transform the natural antibacterial peptides and even design and manufacture of new antibacterial peptides so that they become more lethal.

In this study, the scientists improved based on antibacterial peptide clavanin-A found in the body of a marine organism sea squirt, including the addition of five hydrophobic amino acids to make the entire polypeptide more easily to go into the bacteria. They called the new antibacterial peptides clavanin-MO. In mice, clavanin-MO was found to abolish resistant E. coli and Staphylococcus aureus strains. It also destroys biofilms formed by bacteria on the surface of objects, such as biofilm formed by Pseudomonas aeruginosa found in the lungs of patients with cystic fibrosis.

"Our goal is to find solutions to antibiotic resistance," said Cesar de la Fuente, Ph.D., one of the authors of the paper. Drug-resistant bacteria are expected to exceed cancer and become the number one killer of human health. Antibacterial polypeptide provides an effective alternative: a molecule that can kill resistant bacteria and boost immunity and prevent excessive immune responses."

The researchers plan to further improve the design of antibacterial peptides and eventually put into clinical use. They believe that if combined with traditional antibiotics, it can be more effective in the eradication of bacteria and prevent new drug resistance. Flarebio offers good-quality recombinant proteins like recombinant CDH11.